Abstract: The disclosure relates generally to bacteria that have been modified to metabolize a bile acid, pharmaceutical compositions including the bacteria, and methods of using the bacteria and pharmaceutical compositions to treat disorders associated with an elevated amount of bile acid, e.g., bile acid diarrhea.

Abstract: The present disclosure provides materials and methods for selectively engineering at least one bacterial strain among a mixed population of bacterial strains in the gut of a subject. In some embodiments, a bacteriophage comprising at least one nucleic acid is administered which selectively infects a bacterial strain under conditions that allow expression of the nucleic acid. The present disclosure thus provides compositions and methods for precisely modifying or reducing a population of bacteria in a mixed population in the gut microbiome.